Short communication: the use of sodium ironedetate (Sytron) as an MRI rectal contrast agent.
The use of bowel contrast medium in abdominal and pelvic MRI examinations is increasingly being recognized as a useful adjunct. A contrast agent which produces a negative contrast effect with T2 weighted (T2W) sequences might help distinguish bowel pathology, which has increased signal intensity, from bowel content. A solution of 7.6 mg ml-1 of sodium ironedetate (Sytron, Link Pharmaceuticals) produces positive contrast on the first (proton density) echo and negative contrast (signal void) on the second (T2W) echo of a dual echo sequence at 0.5 T. When administered rectally it provides a negative contrast bowel marker for pelvic examinations.
Buxton
P J
PJ
Department of Radiology, Royal Naval Hospital Haslar, Gosport, UK.
D000285:Administration, Rectal; D003287:Contrast Media; D004492:Edetic Acid; D005290:Ferric Compounds; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis*
D003287:Contrast Media; D005290:Ferric Compounds; D004492:Edetic Acid; C019179:Fe(III)-EDTA